Publication
Detection of ESR1 mutations in circulating cell-free DNA from patients with metastatic breast cancer treated with palbociclib and letrozole.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (5)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 5
- cancerMalignant Breast Neoplasmcivic_curation1.00
- drugLetrozolecivic_curation1.00
- drugPalbociclibcivic_curation1.00
- geneESR1civic_curation1.00
- variantESR1 D538Gcivic_curation1.00
Curated evidence
Evidence citing this paper (3)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 28978004
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| ESR1 D538G1 | ||||||||
| Letrozole + PalbociclibCombination | Malignant Breast Neoplasm | Predictive | C | Does Not Support Sensitivity Response | 2 | accepted | EID4814In a study of 16 patients with metastatic breast cancer (NCT02142868) treated with palbociclib in combination with letrozole, patients with ESR1 mutations (5/16), including ESR1 D538G (n=2), detected … (full text at CIViC) PMID 28978004 · Gyanchandani et al., 2017 · Open in CIViC | civic |
| ESR1 Y537N1 | ||||||||
| Palbociclib | Malignant Breast Neoplasm | Predictive | B | Supports Sensitivity Response | 2 | submitted | EID4817In a study of 16 metastatic breast cancer patients (NCT02142868) treated with palbociclib in combination with letrozole, patients with ESR1 mutations (5/16) detected at initial blood draw, including E… (full text at CIViC) PMID 28978004 · Gyanchandani et al., 2017 · Open in CIViC | civic |
| ESR1 Y537S1 | ||||||||
| Palbociclib | Malignant Breast Neoplasm | Predictive | B | Supports Sensitivity Response | 2 | submitted | EID4819In a study of 16 metastatic breast cancer patients (NCT02142868) treated with palbociclib in combination with letrozole, patients with ESR1 mutations (5/16) detected at initial blood draw, including E… (full text at CIViC) PMID 28978004 · Gyanchandani et al., 2017 · Open in CIViC | civic |